154 related articles for article (PubMed ID: 18182780)
1. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse.
Seubert P; Barbour R; Khan K; Motter R; Tang P; Kholodenko D; Kling K; Schenk D; Johnson-Wood K; Schroeter S; Gill D; Jacobsen JS; Pangalos M; Basi G; Games D
Neurodegener Dis; 2008; 5(2):65-71. PubMed ID: 18182780
[TBL] [Abstract][Full Text] [Related]
2. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
Bard F; Barbour R; Cannon C; Carretto R; Fox M; Games D; Guido T; Hoenow K; Hu K; Johnson-Wood K; Khan K; Kholodenko D; Lee C; Lee M; Motter R; Nguyen M; Reed A; Schenk D; Tang P; Vasquez N; Seubert P; Yednock T
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2023-8. PubMed ID: 12566568
[TBL] [Abstract][Full Text] [Related]
3. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.
DeMattos RB; Bales KR; Cummins DJ; Paul SM; Holtzman DM
Science; 2002 Mar; 295(5563):2264-7. PubMed ID: 11910111
[TBL] [Abstract][Full Text] [Related]
4. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.
Bard F; Cannon C; Barbour R; Burke RL; Games D; Grajeda H; Guido T; Hu K; Huang J; Johnson-Wood K; Khan K; Kholodenko D; Lee M; Lieberburg I; Motter R; Nguyen M; Soriano F; Vasquez N; Weiss K; Welch B; Seubert P; Schenk D; Yednock T
Nat Med; 2000 Aug; 6(8):916-9. PubMed ID: 10932230
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
Geylis V; Steinitz M
Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
[TBL] [Abstract][Full Text] [Related]
6. Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology.
DaSilva K; Brown ME; Westaway D; McLaurin J
Neurobiol Dis; 2006 Aug; 23(2):433-44. PubMed ID: 16766202
[TBL] [Abstract][Full Text] [Related]
7. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576.
Chauhan NB; Siegel GJ
J Neurosci Res; 2003 Oct; 74(1):142-7. PubMed ID: 13130516
[TBL] [Abstract][Full Text] [Related]
8. Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice.
Bard F; Fox M; Friedrich S; Seubert P; Schenk D; Kinney GG; Yednock T
Exp Neurol; 2012 Nov; 238(1):38-43. PubMed ID: 22892246
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner.
Thal DR; Capetillo-Zarate E; Schultz C; Rüb U; Saido TC; Yamaguchi H; Haass C; Griffin WS; Del Tredici K; Braak H; Ghebremedhin E
Acta Neuropathol; 2005 Nov; 110(5):459-71. PubMed ID: 16195918
[TBL] [Abstract][Full Text] [Related]
10. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.
Bacher M; Depboylu C; Du Y; Noelker C; Oertel WH; Behr T; Henriksen G; Behe M; Dodel R
Neurosci Lett; 2009 Jan; 449(3):240-5. PubMed ID: 18786612
[TBL] [Abstract][Full Text] [Related]
11. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.
Dodart JC; Bales KR; Gannon KS; Greene SJ; DeMattos RB; Mathis C; DeLong CA; Wu S; Wu X; Holtzman DM; Paul SM
Nat Neurosci; 2002 May; 5(5):452-7. PubMed ID: 11941374
[TBL] [Abstract][Full Text] [Related]
12. Abeta N-terminal-end specific antibody reduced beta-amyloid in Alzheimer-model mice.
Horikoshi Y; Mori T; Maeda M; Kinoshita N; Sato K; Yamaguchi H
Biochem Biophys Res Commun; 2004 Dec; 325(2):384-7. PubMed ID: 15530403
[TBL] [Abstract][Full Text] [Related]
13. Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo.
Gaugler MN; Tracy J; Kuhnle K; Crameri A; Nitsch RM; Mohajeri MH
FEBS Lett; 2005 Jan; 579(3):753-6. PubMed ID: 15670841
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice.
Bach P; Tschäpe JA; Kopietz F; Braun G; Baade JK; Wiederhold KH; Staufenbiel M; Prinz M; Deller T; Kalinke U; Buchholz CJ; Müller UC
J Immunol; 2009 Jun; 182(12):7613-24. PubMed ID: 19494285
[TBL] [Abstract][Full Text] [Related]
15. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.
Gervais F; Paquette J; Morissette C; Krzywkowski P; Yu M; Azzi M; Lacombe D; Kong X; Aman A; Laurin J; Szarek WA; Tremblay P
Neurobiol Aging; 2007 Apr; 28(4):537-47. PubMed ID: 16675063
[TBL] [Abstract][Full Text] [Related]
16. A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice.
Philipson O; Hammarström P; Nilsson KP; Portelius E; Olofsson T; Ingelsson M; Hyman BT; Blennow K; Lannfelt L; Kalimo H; Nilsson LN
Neurobiol Aging; 2009 Sep; 30(9):1393-405. PubMed ID: 18192084
[TBL] [Abstract][Full Text] [Related]
17. [Immunologic tolerance of anti-Abeta antibody in the sera of AD patients].
Yang ZY; Wang HQ; Xu J; Xie Y; Yuan QF; Yao ZB
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Oct; 23(10):929-31. PubMed ID: 17908502
[TBL] [Abstract][Full Text] [Related]
18. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain.
Tamura Y; Hamajima K; Matsui K; Yanoma S; Narita M; Tajima N; Xin KQ; Klinman D; Okuda K
Neurobiol Dis; 2005 Nov; 20(2):541-9. PubMed ID: 15908227
[TBL] [Abstract][Full Text] [Related]
19. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease.
Wang YJ; Pollard A; Zhong JH; Dong XY; Wu XB; Zhou HD; Zhou XF
Neurobiol Aging; 2009 Mar; 30(3):364-76. PubMed ID: 17686552
[TBL] [Abstract][Full Text] [Related]
20. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
Meli G; Visintin M; Cannistraci I; Cattaneo A
J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
